Angerio Allan D
School of Nursing and Health Studies, Georgetown University, Washington, DC, USA.
Crit Care Nurs Q. 2006 Apr-Jun;29(2):152-6. doi: 10.1097/00002727-200604000-00009.
Acute renal failure presents a serious and life-threatening problem in hospitalized patients. Current therapies address the systemic alterations in renal failure. Cellular changes also occur. These changes affect the glomerular filtration rate and the integrity of the glomerular membrane. ET-1, the most potent vasoconstrictor known, has a negative effect on both the rate of filtration and the integrity of the filtering membrane in renal failure. Using ET-1 antagonists along with the current therapies may prove useful in patients.
急性肾衰竭在住院患者中是一个严重且危及生命的问题。目前的治疗方法针对肾衰竭的全身改变。细胞变化也会发生。这些变化会影响肾小球滤过率和肾小球膜的完整性。ET-1是已知最强效的血管收缩剂，对肾衰竭患者的滤过率和滤过膜完整性均有负面影响。在当前治疗方法的基础上使用ET-1拮抗剂可能对患者有益。
